Zura Bio (ZURA) Competitors

Heron Therapeutics (NASDAQ:HRTX) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.

Which has stronger valuation and earnings, HRTX or ZURA?

Zura Bio has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$144.29M	2.05	-$110.56M	-$0.09	-21.57
Zura Bio	N/A	N/A	-$69.24M	-$0.53	-2.12

Which has more volatility and risk, HRTX or ZURA?

Heron Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500.

Is HRTX or ZURA more profitable?

Zura Bio has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.31%. Heron Therapeutics' return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.31%	N/A	-12.72%
Zura Bio	N/A	-37.36%	-29.81%

Do analysts rate HRTX or ZURA?

Heron Therapeutics currently has a consensus price target of $5.67, indicating a potential upside of 191.95%. Zura Bio has a consensus price target of $14.67, indicating a potential upside of 1,203.70%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts clearly believe Zura Bio is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zura Bio	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Does the media favor HRTX or ZURA?

In the previous week, Heron Therapeutics had 1 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Heron Therapeutics and 4 mentions for Zura Bio. Heron Therapeutics' average media sentiment score of 1.00 beat Zura Bio's score of -0.07 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in HRTX or ZURA?

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 5.8% of Heron Therapeutics shares are owned by company insiders. Comparatively, 22.1% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community favor HRTX or ZURA?

Heron Therapeutics received 645 more outperform votes than Zura Bio when rated by MarketBeat users. However, 79.31% of users gave Zura Bio an outperform vote while only 68.87% of users gave Heron Therapeutics an outperform vote.

Company	Underperform	Outperform
Heron Therapeutics	Outperform Votes 668 68.87%	Underperform Votes 302 31.13%
Zura Bio	Outperform Votes 23 79.31%	Underperform Votes 6 20.69%

Summary

Heron Therapeutics and Zura Bio tied by winning 9 of the 18 factors compared between the two stocks.